Technology HCV 3'NTR

 
 
 

HCV 3' NTR

The 3' Nontranslated Region (3'NTR) is the most conserved region of the HCV genome Kolykhalov et al., J. Virology 70:3363, 1996 ; Blight, KJ and Rice, CM., J. Virology 71:7345, 1997).  It is likely to be a critical regulatory region and it has been shown to be required for replication of an infectious clone of HCV in chimpanzees Kolykhalov et al., Science 277:570, 1997. The 3' NTR is, therefore, an excellent genomic (RNA) target for an anti-HCV therapy.

HCV genome organization

ntr_1.gif (16262 bytes)
Translation initiation Internal ribosome entry site
Minus-strand initiation




 


HCV 3' NTR 98 bp terminus

1a    GGTGGCTCCATCTTAGCCCTAGTCACGGCTAGCTGTGAAAGGTCCGTGAGCCGCATGACTGCAGAGAGTGCTGATACTGGCCTCTCTGCAGATCATGT
1a    ..................................................................................................
1a    ...................................................g..................................c...........
1a    ...................................................g.....................................t........ 
1b    ..........................................................................a.......................
1b    ..................................................................................................
1b    ..................................................................................c...............
1b    ..................................................................................c...............
1b    ................................................................g.................................
1b    ..................................................................................................
1b    ..................................................................................................
1b    ..................................................................................................
1b    ..................................................................................................
1b    ..................................................................................................
1b    ..................................................................................................
1b    ..................................................................................................
2a    .......................................................................c.ta.....t.................
2a    .......................................................................c.ta.....t.................
2b    .......................................................................c.ta.....t.................
3a    ..................................................................................................
3b    ......................................................t..................ta....................a..
3     ......................................................t........................................a..
4?    ..................................................................................................
4a    ..........................................................................a.......................
6     ..................................................................................................
7     ...........................................................................................t......
8     ..........................................................................a.......................
9     ........................................................................../.......................
Nucleotide sequence in the 3' NTR of 28 independently cloned isolates of HCV representing the genotypes shown on the left. Dots represent the same nucleotides as in the first isolate.

U.S. 5,874,565 entitled (and related EP 0856051) was assigned to Washington University and licensed exclusively to Apath.

Apath has already sublicensed exclusive rights to the 3' NTR for diagnostic applications to a major diagnostics company.  Rights to therapeutic applications are currently available for exclusive licensing to interested pharmaceutical companies.

backtop